185 related articles for article (PubMed ID: 15353330)
21. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446
[TBL] [Abstract][Full Text] [Related]
22. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine.
Hartoonian C; Ebtekar M; Soleimanjahi H; Karami A; Mahdavi M; Rastgoo N; Azadmanesh K
Cytokine; 2009 Apr; 46(1):43-50. PubMed ID: 19278866
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori.
Xing Y; Liu W; Li X; Guo L; Lv X; Xi T
Biochem Biophys Res Commun; 2015 Jul; 462(3):269-74. PubMed ID: 25957472
[TBL] [Abstract][Full Text] [Related]
24. Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success.
Davies G
Expert Rev Vaccines; 2008 Apr; 7(3):287-91. PubMed ID: 18393597
[TBL] [Abstract][Full Text] [Related]
25. The impact of size on particulate vaccine adjuvants.
Shah RR; O'Hagan DT; Amiji MM; Brito LA
Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
[TBL] [Abstract][Full Text] [Related]
26. Adjuvants for Animal Vaccines.
Burakova Y; Madera R; McVey S; Schlup JR; Shi J
Viral Immunol; 2018; 31(1):11-22. PubMed ID: 28618246
[TBL] [Abstract][Full Text] [Related]
27. Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines.
Cibulski S; Rivera-Patron M; Suárez N; Pirez M; Rossi S; Yendo AC; de Costa F; Gosmann G; Fett-Neto A; Roehe PM; Silveira F
Vaccine; 2018 Jan; 36(1):55-65. PubMed ID: 29174676
[TBL] [Abstract][Full Text] [Related]
28. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
29. Immunological foundations to the quest for new vaccine adjuvants.
Burdin N; Guy B; Moingeon P
BioDrugs; 2004; 18(2):79-93. PubMed ID: 15046524
[TBL] [Abstract][Full Text] [Related]
30. Will adjuvants be needed for vaccines of the future?
Bomford R
Dev Biol Stand; 1998; 92():13-7. PubMed ID: 9554255
[TBL] [Abstract][Full Text] [Related]
31. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.
Barouch DH; Letvin NL; Seder RA
Immunol Rev; 2004 Dec; 202():266-74. PubMed ID: 15546399
[TBL] [Abstract][Full Text] [Related]
32. Current adjuvants and new perspectives in vaccine formulation.
Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
[TBL] [Abstract][Full Text] [Related]
33. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
[TBL] [Abstract][Full Text] [Related]
34. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants.
Fujihashi K; Koga T; van Ginkel FW; Hagiwara Y; McGhee JR
Vaccine; 2002 Jun; 20(19-20):2431-8. PubMed ID: 12057597
[TBL] [Abstract][Full Text] [Related]
35. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
36. The use of CpG DNA as a mucosal vaccine adjuvant.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
[TBL] [Abstract][Full Text] [Related]
37. Adjuvants in perspective.
Vogel FR
Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
[TBL] [Abstract][Full Text] [Related]
38. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
39. Adjuvants and immunostimulants in fish vaccines: current knowledge and future perspectives.
Tafalla C; Bøgwald J; Dalmo RA
Fish Shellfish Immunol; 2013 Dec; 35(6):1740-50. PubMed ID: 23507338
[TBL] [Abstract][Full Text] [Related]
40. Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
Shah RR; Hassett KJ; Brito LA
Methods Mol Biol; 2017; 1494():1-13. PubMed ID: 27718182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
